Skip to content

Disease-modifying therapies

TL;DR — Sprifermin increased femorotibial cartilage thickness at two years without significantly improving WOMAC scores, while metformin remains supported mainly by preclinical and limited human evidence that still requires confirmatory clinical trials (Hochberg 2019, PMID 31593273; Lim 2022, PMID 35597372).

Decision frame

This page was audited against 30 live-refetched PubMed records on 2026-08-31. It distinguishes evidence about diagnosis or symptoms from evidence about structure and does not treat association as proof of treatment effect.

Audit interpretation safeguards

  • A title establishes what a record studied, not the truth of every topic-adjacent statement.
  • Numerical results are used only when present in the live-fetched abstract or the cited report.
  • Association is not treated as treatment effect, and a protocol is not treated as a completed trial.
  • Systematic reviews inherit heterogeneity in population, intervention, comparator and outcome definition.

Target classes

Domain What the evidence supports What remains uncertain
Sprifermin At 100 µg every 6 or 12 months, sprifermin increased femorotibial cartilage thickness at two years but did not significantly improve total WOMAC scores versus placebo. (Hochberg 2019, PMID 31593273) Clinical importance and durability were uncertain.
Metformin Preclinical studies consistently suggested chondroprotective, immunomodulatory and analgesic effects, but human evidence was limited and confirmatory clinical trials were still needed. (Lim 2022, PMID 35597372) The review did not establish clinical efficacy or an approved OA indication.

Structure without symptoms, symptoms without safe structure

Sprifermin (rhFGF18). FORWARD (NCT01919164 COMPLETED): 100 µg every 6 months increased 2-year femorotibial cartilage thickness 0.05 mm (95% CI 0.03–0.07) vs placebo; 100 µg every 12 months 0.04 mm (0.02–0.06); 30 µg doses not significant; no significant WOMAC difference at any dose (Hochberg 2019, PMID 31593273). Five-year follow-up (378/549 completers): the 0.05 mm difference for 100 µg q6mo vs placebo persisted (0.00–0.10; p=0.015), while WOMAC pain improved about 50% in every group, including placebo (Eckstein 2021, PMID 33962962). FGF18 is a genetically nominated target (Tachmazidou 2019, PMID 30664745), but the structural result has not established patient-important symptom benefit.

Lorecivivint (CLK2/DYRK1A; Wnt modulator). Phase 2 primary WOMAC pain week 13 was not met; all arms including placebo improved ≥20 points (Yazici 2020, PMID 32432388). Phase 2b found 0.07 mg and 0.23 mg improved Pain NRS vs placebo at weeks 12 and 24 (e.g. 0.07 mg week 24 −0.70, 95% CI −1.34 to −0.06) (Yazici 2021, PMID 33588087). Phase 3 OA-11 (n=513): Pain NRS week 12 LOR −2.24 vs placebo −2.49 (p=0.185); no medial JSW loss in either arm over 52 weeks (Yazici 2025, PMID 39808286). OA-10 (n=498) also missed the primary; a post-hoc KL 2 subgroup showed a week-4 signal (Yazici 2025, PMID 39808288). NCT04931667 (3-year open-label) was TERMINATED; NCT04385303 (STRIDES-1) COMPLETED.

NGF inhibition (tanezumab). Lane 2010: walking-pain reductions 45–62% vs 22% placebo across 10–200 µg/kg (Lane 2010, PMID 20942668). Schnitzer 2019: WOMAC Pain least-squares difference vs placebo −0.60 (2.5 mg) and −0.73 (2.5/5 mg) at week 16 (Schnitzer 2019, PMID 31265100; NCT02697773 COMPLETED). Versus continued NSAIDs, composite joint-safety events were 38.3 (95% CI 28.0–52.5) and 71.5 (56.7–90.2) per 1,000 patient-years at 2.5 and 5 mg vs 14.8 (8.9–24.6) on NSAIDs (Hochberg 2021, PMID 33538113). Pooled SC studies: 145/4,541 (3.2%) adjudicated composite joint-safety endpoint; 0% placebo, 3.2% 2.5 mg, 6.2% 5 mg, 1.5% NSAID (Carrino 2023, PMID 37652258). Analgesia uncoupled from joint protection is the unresolved safety problem (OQ-7).

Bone-targeted and anti-inflammatory attempts. MIV-711 (cathepsin K): NRS pain −1.4 / −1.7 / −1.5 (placebo / 100 / 200 mg) — not significant — while slowing medial femoral bone-area progression (p=0.002 and 0.004) (Conaghan 2020, PMID 31887743). Doxycycline slowed medial joint-space narrowing (0.15±0.42 vs 0.24±0.54 mm in one report of the trial) without reducing pain (Brandt 2005, PMID 15986343). Low-dose methotrexate in knee OA with effusion-synovitis (n=215; NCT03815448 COMPLETED): VAS pain difference 0.3 mm (−6.7 to 7.3) and effusion-synovitis area 0.1 cm² (−0.8 to 1.0) at 52 weeks — null (Zhu 2025, PMID 40455462). Metformin remains preclinical-plus-limited-human (Lim 2022, PMID 35597372).

Evidence map

The table catalogs the retrieved studies used to bound this page. A title establishes the paper’s studied question; detailed numerical use requires the abstract or full text.

Study Design signal Evidence contribution Main transfer limit
Cho 2021 (PMID 34848838) review Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Perruccio 2024 (PMID 38035975) review Osteoarthritis year in review 2023: Epidemiology & therapy. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Zhou 2024 (PMID 39122910) review Ion channels in osteoarthritis: emerging roles and potential targets. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Lv 2021 (PMID 34513847) review Molecular Classification of Knee Osteoarthritis. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Pye 2022 (PMID 35285032) review Advances in the pharmaceutical treatment options for canine osteoarthritis. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Lim 2022 (PMID 35597372) systematic review Metformin as a potential disease-modifying drug in osteoarthritis: a systematic review of pre-clinical and human studies. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Oo 2024 (PMID 38942581) review Prospects of Disease-Modifying Osteoarthritis Drugs. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Oo 2022 (PMID 35410687) review Prospects of Disease-Modifying Osteoarthritis Drugs. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Hochberg 2019 (PMID 31593273) randomized trial Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWA…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Gregori 2018 (PMID 30575881) network meta-analysis Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and …. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Conaghan 2025 (PMID 39734047) randomized trial Exploring a novel outcome measure of symptom progression in knee osteoarthritis utilizing a large randomized trial. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Guehring 2021 (PMID 33752164) randomized trial The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Roemer 2016 (PMID 27393009) randomized trial Structural effects of sprifermin in knee osteoarthritis: a post-hoc analysis on cartilage and non-cartilaginous tissue alterations i…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Lohmander 2014 (PMID 24740822) randomized trial Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placeb…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Eckstein 2021 (PMID 33962962) randomized trial Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Dahlberg 2016 (PMID 27050139) randomized trial A first-in-human, double-blind, randomised, placebo-controlled, dose ascending study of intra-articular rhFGF18 (sprifermin) in pati…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Brett 2020 (PMID 32860991) randomized trial Automated MRI assessment confirms cartilage thickness modification in patients with knee osteoarthritis: post-hoc analysis from a ph…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Eckstein 2024 (PMID 39286575) journal study Unbiased analysis of knee cartilage thickness change over three years after sprifermin vs. placebo treatment - A post-hoc analysis f…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Eckstein 2020 (PMID 32098758) randomized trial Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibi…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Roemer 2020 (PMID 32619609) randomized trial Evaluating the structural effects of intra-articular sprifermin on cartilage and non-cartilaginous tissue alterations, based on sqMR…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Tambiah 2022 (PMID 35005990) randomized trial Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Cl…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Yazici 2020 (PMID 32432388) randomized trial Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor a…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Yazici 2025 (PMID 39808288) randomized trial A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Yazici 2021 (PMID 33588087) randomized trial A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoa…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Tambiah 2021 (PMID 34101138) journal study Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Shah 2026 (PMID 42402776) meta-analysis Efficacy and safety of lorecivivint for the treatment of knee osteoarthritis: A systematic review and meta-analysis of randomized co…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Yazici 2025 (PMID 39808286) randomized trial A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes …. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Yazici 2017 (PMID 28711582) randomized trial A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, ra…. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Katz 2021 (PMID 33560326) review Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. Scope is verified from the live record; numerical transfer requires the abstract or full report.
Conaghan 2020 (PMID 31887743) randomized trial Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized Controlled Trial. Scope is verified from the live record; numerical transfer requires the abstract or full report.

Audit disposition

Check Result
PubMed identifiers 37/37 unique PMIDs resolved in the 2026-08-31 independent live E-utilities fetch
ClinicalTrials.gov identifiers 5/5 NCT IDs resolved individually and matched in the 2026-08-31 independent v2 API fetch
Author / year / journal Matched to live PubMed metadata; ePub/print offsets tolerated
Claim review Every remaining claim-to-citation pairing was checked against the live-fetched abstract or registry record; unsupported rows were deleted and overbroad claims were narrowed. No substantive citation issue remains.
## Open questions
  • Can any DMOAD meet a hierarchical symptom-plus-structure standard (OQ-6)? Sprifermin has structure without WOMAC; lorecivivint phase 3 missed pain; methotrexate missed both (Hochberg 2019, PMID 31593273; Yazici 2025, PMID 39808286; Zhu 2025, PMID 40455462).
  • What monitoring could uncouple NGF analgesia from rapidly progressive OA (OQ-7)? (Hochberg 2021, PMID 33538113; Carrino 2023, PMID 37652258)
  • Is cartilage-thickness change a surrogate for later replacement or a radiologic curiosity (OQ-16)? FORWARD's 0.05 mm and zero replacements in one arm are hypothesis-generating (Eckstein 2021, PMID 33962962).
  • Should KL 2 be the lorecivivint enrichment rule, or is that a post-hoc trap? (Yazici 2025, PMID 39808288)

References

  1. Cho Y, Jeong S, Kim H, et al. Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions. Exp Mol Med. 2021;53(11);1689-1696. PMID 34848838
  2. Perruccio AV, Young JJ, Wilfong JM, et al. Osteoarthritis year in review 2023: Epidemiology & therapy. Osteoarthritis Cartilage. 2024;32(2);159-165. PMID 38035975
  3. Zhou R, Fu W, Vasylyev D, et al. Ion channels in osteoarthritis: emerging roles and potential targets. Nat Rev Rheumatol. 2024;20(9);545-564. PMID 39122910
  4. Lv Z, Yang YX, Li J, et al. Molecular Classification of Knee Osteoarthritis. Front Cell Dev Biol. 2021;9;725568. PMID 34513847
  5. Pye C, Bruniges N, Peffers M, et al. Advances in the pharmaceutical treatment options for canine osteoarthritis. J Small Anim Pract. 2022;63(10);721-738. PMID 35285032
  6. Lim YZ, Wang Y, Estee M, et al. Metformin as a potential disease-modifying drug in osteoarthritis: a systematic review of pre-clinical and human studies. Osteoarthritis Cartilage. 2022;30(11);1434-1442. PMID 35597372
  7. Oo WM. Prospects of Disease-Modifying Osteoarthritis Drugs. Rheum Dis Clin North Am. 2024;50(3);483-518. PMID 38942581
  8. Oo WM. Prospects of Disease-Modifying Osteoarthritis Drugs. Clin Geriatr Med. 2022;38(2);397-432. PMID 35410687
  9. Hochberg MC, Guermazi A, Guehring H, et al. Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial. JAMA. 2019;322(14);1360-1370. PMID 31593273
  10. Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. JAMA. 2018;320(24);2564-2579. PMID 30575881
  11. Conaghan PG, Katz N, Hunter DJ, et al. Exploring a novel outcome measure of symptom progression in knee osteoarthritis utilizing a large randomized trial. Osteoarthritis Cartilage. 2025;33(3);383-390. PMID 39734047
  12. Guehring H, Moreau F, Daelken B, et al. The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial. Semin Arthritis Rheum. 2021;51(2);450-456. PMID 33752164
  13. Roemer FW, Aydemir A, Lohmander S, et al. Structural effects of sprifermin in knee osteoarthritis: a post-hoc analysis on cartilage and non-cartilaginous tissue alterations in a randomized controlled trial. BMC Musculoskelet Disord. 2016;17;267. PMID 27393009
  14. Lohmander LS, Hellot S, Dreher D, et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66(7);1820-31. PMID 24740822
  15. Eckstein F, Hochberg MC, Guehring H, et al. Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study. Ann Rheum Dis. 2021;80(8);1062-1069. PMID 33962962
  16. Dahlberg LE, Aydemir A, Muurahainen N, et al. A first-in-human, double-blind, randomised, placebo-controlled, dose ascending study of intra-articular rhFGF18 (sprifermin) in patients with advanced knee osteoarthritis. Clin Exp Rheumatol. 2016;34(3);445-50. PMID 27050139
  17. Brett A, Bowes MA, Conaghan PG, et al. Automated MRI assessment confirms cartilage thickness modification in patients with knee osteoarthritis: post-hoc analysis from a phase II sprifermin study. Osteoarthritis Cartilage. 2020;28(11);1432-1436. PMID 32860991
  18. Eckstein F, Maschek S, Wirth W, et al. Unbiased analysis of knee cartilage thickness change over three years after sprifermin vs. placebo treatment - A post-hoc analysis from the phase 2B FORWARD study. Osteoarthr Cartil Open. 2024;6(4);100513. PMID 39286575
  19. Eckstein F, Kraines JL, Aydemir A, et al. Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial. Ann Rheum Dis. 2020;79(4);525-528. PMID 32098758
  20. Roemer FW, Kraines J, Aydemir A, et al. Evaluating the structural effects of intra-articular sprifermin on cartilage and non-cartilaginous tissue alterations, based on sqMRI assessment over 2 years. Osteoarthritis Cartilage. 2020;28(9);1229-1234. PMID 32619609
  21. Tambiah JRS, Simsek I, Swearingen CJ, et al. Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint. Am J Sports Med. 2022;50(3);630-636. PMID 35005990
  22. Yazici Y, McAlindon TE, Gibofsky A, et al. Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial. Arthritis Rheumatol. 2020;72(10);1694-1706. PMID 32432388
  23. Yazici Y, Tambiah JRS, Swearingen CJ, et al. A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients. Clin Exp Rheumatol. 2025;43(5);847-853. PMID 39808288
  24. Yazici Y, McAlindon TE, Gibofsky A, et al. A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthritis Cartilage. 2021;29(5);654-666. PMID 33588087
  25. Tambiah JRS, Kennedy S, Swearingen CJ, et al. Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial. Rheumatol Ther. 2021;8(2);973-985. PMID 34101138
  26. Shah SAA, Sachdev DS, Shahid ZUA, et al. Efficacy and safety of lorecivivint for the treatment of knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. J Orthop Surg (Hong Kong). 2026;34(2);10225536261466342. PMID 42402776
  27. Yazici Y, Tambiah JRS, Swearingen CJ, et al. A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis. Clin Exp Rheumatol. 2025;43(5);854-860. PMID 39808286
  28. Yazici Y, McAlindon TE, Fleischmann R, et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage. 2017;25(10);1598-1606. PMID 28711582
  29. Katz JN, Arant KR, Loeser RF. Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. JAMA. 2021;325(6);568-578. PMID 33560326
  30. Conaghan PG, Bowes MA, Kingsbury SR, et al. Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized Controlled Trial. Ann Intern Med. 2020;172(2);86-95. PMID 31887743
  31. Tachmazidou I, Hatzikotoulas K, Southam L, et al. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat Genet. 2019;51:230-236. PMID 30664745
  32. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363:1521-31. PMID 20942668
  33. Schnitzer TJ, Easton R, Pang S, et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis. JAMA. 2019;322:37-48. PMID 31265100
  34. Hochberg MC, Carrino JA, Schnitzer TJ, et al. Long-term safety and efficacy of subcutaneous tanezumab versus NSAIDs for hip or knee osteoarthritis. Arthritis Rheumatol. 2021;73:1167-1177. PMID 33538113
  35. Carrino JA, McAlindon TE, Schnitzer TJ, et al. Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab. Osteoarthritis Cartilage. 2023;31:1612-1626. PMID 37652258
  36. Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis. Arthritis Rheum. 2005;52:2015-25. PMID 15986343
  37. Zhu Z, Yu Q, Leng X, et al. Low-dose methotrexate for the treatment of inflammatory knee osteoarthritis. JAMA Intern Med. 2025;185:808-816. PMID 40455462